Back to Authors

Wierenga, Klaas

Mayo Clinic

Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL 32224, USA.

Citations 2

Haploinsufficiency as a disease mechanism in GNB1 ‐associated neurodevelopmental disorder
Schultz‐Rogers, Laura , Masuho, Ikuo , Schmitz, Christopher T., Schwab, Tanya L., Gunderson, Lauren, Pichurin, Pavel N. , Wierenga, Klaas J. , Martemyanov, Kirill A. , Klee, Eric W. , Pinto E Vairo, Filippo, Wierenga, Klaas, Klee, Eric W , Schmitz, Christopher , Vairo, Filippo Pinto e , Clark, Karl J.

Molecular Genetics & Genomic Medicine | September 14, 2020 | Volume: 8 | Issue: 11 | Pages: No page available

10.1002/mgg3.1477 Get It

Abstract Background GNB1 encodes a subunit of a heterotrimeric G‐protein complex that transduces intracellular signaling cascades. Disruptions to the gene have previously been shown to be embryonic lethal in knockout mice and to cause complex neurodevelopmental disorders in humans. To date, the majority of variants associated with disease in humans have been missense variants in exons 5‐7. Methods Genetic sequencing was performed on two patients presenting with complex neurological phenotypes including intellectual disability, hypotonia, and in one patient seizures. Reported variants were assessed using RNA sequencing and functional BRET/BiFC assays. Results A splice variant reported in patient 1 was confirmed to cause usage of a cryptic splice site leading to a truncated protein product. Patient 2 was reported to have a truncating variant. BRET and BiFC assays of both patient variants confirmed both were deficient in inducing GPCR‐induced G protein activation due to lack of dimer formation with the Gγ subunit. Conclusion Here, we report two patients with functionally confirmed loss of function variants in GNB1 and neurodevelopmental phenotypes including intellectual disability, hypotonia, and seizures in one patient. These results suggest haploinsufficiency of GNB1 is a mechanism for neurodevelopmental disorders in humans.
Genomic Observations of a Rare/Pathogenic SMAD3 Variant in Loeys–Dietz Syndrome 3 Confirmed by Protein Informatics and Structural Investigations
Richter, John E. , Samreen, Ayesha , Vadlamudi, Charitha , Helmi, Haytham , Mohammad, Ahmed N. , Wierenga, Klaas J. , Hines, Stephanie L., Caulfield, Thomas R. , Wierenga, Klaas, Hines, Stephanie, Caulfield, Thomas R , Samreen, Ayesha , Atwal, Paldeep S

Medicina | May 15, 2019 | Volume: 55 | Issue: 5 | Pages: 137

10.3390/medicina55050137 Get It

Background and objectives: Loeys–Dietz syndrome 3, also known as aneurysms-–osteoarthritis syndrome, is an autosomal dominant genetic connective tissue disease caused by pathogenic variants in SMAD3, a transcription factor involved in TGF-β signaling. This disorder is characterized by early-onset osteoarthritis and arterial aneurysms. Common features include scoliosis, uvula abnormalities, striae, and velvety skin. Materials and Methods: The pathogenicity of a variant of uncertain significance in the SMAD3 gene was evaluated (variant c.220C > T) through personalized protein informatics and molecular studies. Results: The case of a 44-year-old male, who was originally presumed to have Marfan syndrome, is presented. An expanded gene panel determined the probable cause to be a variant in SMAD3, c.220C > T (p.R74W). His case was complicated by a history of stroke, but his phenotype was otherwise characteristic for Loeys–Dietz syndrome 3. Conclusion: This case emphasizes the importance of comprehensive genetic testing to evaluate patients for connective tissue disorders, as well as the potential benefit of utilizing a protein informatics platform for the assessment of variant pathogenicity.